================================================================================
BLOOD CANCER CLASSIFICATION DIFFERENCES REPORT
WHO 2022 vs ICC 2022 Classifications
================================================================================

SUMMARY STATISTICS
----------------------------------------
Total test cases analyzed: 204
Cases with differences: 83
Disease type disagreements: 72

CLINICAL IMPACT SUMMARY
----------------------------------------
Critical Impact (Score ‚â•80): 9
High Impact (Score 50-79): 33
Medium Impact (Score 25-49): 33
Low Impact (Score 1-24): 8
Minimal Impact (Score 0): 121

üö® CRITICAL CLINICAL IMPACT CASES (Score ‚â•80)
============================================================
These differences have major treatment and outcome implications

CRITICAL CASE #1 (Impact Score: 85)
----------------------------------------
WHO 2022: AML with NPM1 mutation
ICC 2022: MDS with excess blasts

üè• CLINICAL CONSEQUENCES:
  ‚Ä¢ Fundamental disease classification disagreement
  ‚Ä¢ Targeted therapy eligibility differs: {'npm1'}

üíä TREATMENT IMPLICATIONS:
  ‚Ä¢ Intensive chemotherapy vs supportive care
  ‚Ä¢ Stem cell transplant eligibility differs
  ‚Ä¢ Clinical trial eligibility differs

üî¨ MRD MONITORING IMPLICATIONS:
  ‚Ä¢ Molecular vs flow cytometry MRD monitoring
  ‚Ä¢ Different sensitivity and specificity

üìä PROGNOSTIC IMPLICATIONS:
  ‚Ä¢ Risk category: Favorable vs Unknown
  ‚Ä¢ Different survival expectations
  ‚Ä¢ Different treatment intensity recommendations

üìã TEST CASE DETAILS:
  ‚Ä¢ Age: unknown
  ‚Ä¢ Blast %: 9

------------------------------------------------------------

CRITICAL CASE #2 (Impact Score: 80)
----------------------------------------
WHO 2022: MDS with biallelic TP53 inactivation
ICC 2022: MDS/AML, NOS

üè• CLINICAL CONSEQUENCES:
  ‚Ä¢ Fundamental disease classification disagreement
  ‚Ä¢ Targeted therapy eligibility differs: {'tp53'}

üíä TREATMENT IMPLICATIONS:
  ‚Ä¢ Intensive chemotherapy vs supportive care
  ‚Ä¢ Stem cell transplant eligibility differs
  ‚Ä¢ Clinical trial eligibility differs
  ‚Ä¢ TP53-directed therapy considerations

üìä PROGNOSTIC IMPLICATIONS:
  ‚Ä¢ Risk category: High vs Intermediate
  ‚Ä¢ Different survival expectations
  ‚Ä¢ Different treatment intensity recommendations

üìã TEST CASE DETAILS:
  ‚Ä¢ Age: unknown
  ‚Ä¢ Blast %: 10

------------------------------------------------------------

CRITICAL CASE #3 (Impact Score: 80)
----------------------------------------
WHO 2022: MDS with biallelic TP53 inactivation
ICC 2022: MDS/AML, NOS

üè• CLINICAL CONSEQUENCES:
  ‚Ä¢ Fundamental disease classification disagreement
  ‚Ä¢ Targeted therapy eligibility differs: {'tp53'}

üíä TREATMENT IMPLICATIONS:
  ‚Ä¢ Intensive chemotherapy vs supportive care
  ‚Ä¢ Stem cell transplant eligibility differs
  ‚Ä¢ Clinical trial eligibility differs
  ‚Ä¢ TP53-directed therapy considerations

üìä PROGNOSTIC IMPLICATIONS:
  ‚Ä¢ Risk category: High vs Intermediate
  ‚Ä¢ Different survival expectations
  ‚Ä¢ Different treatment intensity recommendations

üìã TEST CASE DETAILS:
  ‚Ä¢ Age: unknown
  ‚Ä¢ Blast %: 15

------------------------------------------------------------

CRITICAL CASE #4 (Impact Score: 90)
----------------------------------------
WHO 2022: AML, myelodysplasia related
ICC 2022: AML with mutated TP53

üè• CLINICAL CONSEQUENCES:
  ‚Ä¢ Targeted therapy eligibility differs: {'tp53'}
  ‚Ä¢ Subtype classification differences within same disease category
  ‚Ä¢ Therapy-related classification differs
  ‚Ä¢ Genetic marker terminology differs

üíä TREATMENT IMPLICATIONS:
  ‚Ä¢ TP53-directed therapy considerations
  ‚Ä¢ Different approach to therapy-related disease

üî¨ MRD MONITORING IMPLICATIONS:
  ‚Ä¢ Flow cytometry MRD only for both classifications
  ‚Ä¢ Different genetic marker identification may affect MRD strategy

üìä PROGNOSTIC IMPLICATIONS:
  ‚Ä¢ Risk category: Intermediate vs High
  ‚Ä¢ Different survival expectations
  ‚Ä¢ Different treatment intensity recommendations
  ‚Ä¢ Potentially different prognosis within disease type
  ‚Ä¢ Different prognosis for therapy-related vs de novo disease

üìã TEST CASE DETAILS:
  ‚Ä¢ Age: unknown
  ‚Ä¢ Blast %: 20

------------------------------------------------------------

CRITICAL CASE #5 (Impact Score: 90)
----------------------------------------
WHO 2022: AML, myelodysplasia related
ICC 2022: AML with mutated TP53

üè• CLINICAL CONSEQUENCES:
  ‚Ä¢ Targeted therapy eligibility differs: {'tp53'}
  ‚Ä¢ Subtype classification differences within same disease category
  ‚Ä¢ Therapy-related classification differs
  ‚Ä¢ Genetic marker terminology differs

üíä TREATMENT IMPLICATIONS:
  ‚Ä¢ TP53-directed therapy considerations
  ‚Ä¢ Different approach to therapy-related disease

üî¨ MRD MONITORING IMPLICATIONS:
  ‚Ä¢ Flow cytometry MRD only for both classifications
  ‚Ä¢ Different genetic marker identification may affect MRD strategy

üìä PROGNOSTIC IMPLICATIONS:
  ‚Ä¢ Risk category: Intermediate vs High
  ‚Ä¢ Different survival expectations
  ‚Ä¢ Different treatment intensity recommendations
  ‚Ä¢ Potentially different prognosis within disease type
  ‚Ä¢ Different prognosis for therapy-related vs de novo disease

üìã TEST CASE DETAILS:
  ‚Ä¢ Age: unknown
  ‚Ä¢ Blast %: 25

------------------------------------------------------------

CRITICAL CASE #6 (Impact Score: 95)
----------------------------------------
WHO 2022: MDS with biallelic TP53 inactivation
ICC 2022: MDS/AML with myelodysplasia related gene mutation

üè• CLINICAL CONSEQUENCES:
  ‚Ä¢ Fundamental disease classification disagreement
  ‚Ä¢ Targeted therapy eligibility differs: {'tp53'}
  ‚Ä¢ Therapy-related classification differs

üíä TREATMENT IMPLICATIONS:
  ‚Ä¢ Intensive chemotherapy vs supportive care
  ‚Ä¢ Stem cell transplant eligibility differs
  ‚Ä¢ Clinical trial eligibility differs
  ‚Ä¢ TP53-directed therapy considerations
  ‚Ä¢ Different approach to therapy-related disease

üìä PROGNOSTIC IMPLICATIONS:
  ‚Ä¢ Risk category: High vs Intermediate
  ‚Ä¢ Different survival expectations
  ‚Ä¢ Different treatment intensity recommendations
  ‚Ä¢ Different prognosis for therapy-related vs de novo disease

üìã TEST CASE DETAILS:
  ‚Ä¢ Age: 75
  ‚Ä¢ Blast %: 12

------------------------------------------------------------

CRITICAL CASE #7 (Impact Score: 90)
----------------------------------------
WHO 2022: AML, myelodysplasia related
ICC 2022: AML with mutated TP53

üè• CLINICAL CONSEQUENCES:
  ‚Ä¢ Targeted therapy eligibility differs: {'tp53'}
  ‚Ä¢ Subtype classification differences within same disease category
  ‚Ä¢ Therapy-related classification differs
  ‚Ä¢ Genetic marker terminology differs

üíä TREATMENT IMPLICATIONS:
  ‚Ä¢ TP53-directed therapy considerations
  ‚Ä¢ Different approach to therapy-related disease

üî¨ MRD MONITORING IMPLICATIONS:
  ‚Ä¢ Flow cytometry MRD only for both classifications
  ‚Ä¢ Different genetic marker identification may affect MRD strategy

üìä PROGNOSTIC IMPLICATIONS:
  ‚Ä¢ Risk category: Intermediate vs High
  ‚Ä¢ Different survival expectations
  ‚Ä¢ Different treatment intensity recommendations
  ‚Ä¢ Potentially different prognosis within disease type
  ‚Ä¢ Different prognosis for therapy-related vs de novo disease

üìã TEST CASE DETAILS:
  ‚Ä¢ Age: unknown
  ‚Ä¢ Blast %: 22

------------------------------------------------------------

CRITICAL CASE #8 (Impact Score: 90)
----------------------------------------
WHO 2022: AML, myelodysplasia related
ICC 2022: AML with mutated TP53

üè• CLINICAL CONSEQUENCES:
  ‚Ä¢ Targeted therapy eligibility differs: {'tp53'}
  ‚Ä¢ Subtype classification differences within same disease category
  ‚Ä¢ Therapy-related classification differs
  ‚Ä¢ Genetic marker terminology differs

üíä TREATMENT IMPLICATIONS:
  ‚Ä¢ TP53-directed therapy considerations
  ‚Ä¢ Different approach to therapy-related disease

üî¨ MRD MONITORING IMPLICATIONS:
  ‚Ä¢ Flow cytometry MRD only for both classifications
  ‚Ä¢ Different genetic marker identification may affect MRD strategy

üìä PROGNOSTIC IMPLICATIONS:
  ‚Ä¢ Risk category: Intermediate vs High
  ‚Ä¢ Different survival expectations
  ‚Ä¢ Different treatment intensity recommendations
  ‚Ä¢ Potentially different prognosis within disease type
  ‚Ä¢ Different prognosis for therapy-related vs de novo disease

üìã TEST CASE DETAILS:
  ‚Ä¢ Age: unknown
  ‚Ä¢ Blast %: 35

------------------------------------------------------------

CRITICAL CASE #9 (Impact Score: 80)
----------------------------------------
WHO 2022: MDS with biallelic TP53 inactivation
ICC 2022: MDS/AML, NOS

üè• CLINICAL CONSEQUENCES:
  ‚Ä¢ Fundamental disease classification disagreement
  ‚Ä¢ Targeted therapy eligibility differs: {'tp53'}

üíä TREATMENT IMPLICATIONS:
  ‚Ä¢ Intensive chemotherapy vs supportive care
  ‚Ä¢ Stem cell transplant eligibility differs
  ‚Ä¢ Clinical trial eligibility differs
  ‚Ä¢ TP53-directed therapy considerations

üìä PROGNOSTIC IMPLICATIONS:
  ‚Ä¢ Risk category: High vs Intermediate
  ‚Ä¢ Different survival expectations
  ‚Ä¢ Different treatment intensity recommendations

üìã TEST CASE DETAILS:
  ‚Ä¢ Age: unknown
  ‚Ä¢ Blast %: 15

------------------------------------------------------------

‚ö†Ô∏è  HIGH CLINICAL IMPACT CASES (Score 50-79)
============================================================
These differences have significant clinical implications

HIGH IMPACT CASE #1 (Impact Score: 70)
----------------------------------------
WHO 2022: MDS with increased blasts 2
ICC 2022: AML with in-frame bZIP mutated CEBPA

üíä Key Treatment Differences:
  ‚Ä¢ Intensive chemotherapy vs supportive care
  ‚Ä¢ Stem cell transplant eligibility differs
  ‚Ä¢ Clinical trial eligibility differs


HIGH IMPACT CASE #2 (Impact Score: 65)
----------------------------------------
WHO 2022: MDS with increased blasts 2
ICC 2022: AML with t(9;22)(q34.1;q11.2)/BCR::ABL1

üíä Key Treatment Differences:
  ‚Ä¢ Intensive chemotherapy vs supportive care
  ‚Ä¢ Stem cell transplant eligibility differs
  ‚Ä¢ Clinical trial eligibility differs

üî¨ MRD Monitoring Differences:
  ‚Ä¢ Molecular vs flow cytometry MRD monitoring
  ‚Ä¢ Different sensitivity and specificity


HIGH IMPACT CASE #3 (Impact Score: 70)
----------------------------------------
WHO 2022: MDS with increased blasts 2
ICC 2022: AML with in-frame bZIP mutated CEBPA

üíä Key Treatment Differences:
  ‚Ä¢ Intensive chemotherapy vs supportive care
  ‚Ä¢ Stem cell transplant eligibility differs
  ‚Ä¢ Clinical trial eligibility differs


HIGH IMPACT CASE #4 (Impact Score: 65)
----------------------------------------
WHO 2022: MDS with increased blasts 2
ICC 2022: AML with t(9;22)(q34.1;q11.2)/BCR::ABL1

üíä Key Treatment Differences:
  ‚Ä¢ Intensive chemotherapy vs supportive care
  ‚Ä¢ Stem cell transplant eligibility differs
  ‚Ä¢ Clinical trial eligibility differs

üî¨ MRD Monitoring Differences:
  ‚Ä¢ Molecular vs flow cytometry MRD monitoring
  ‚Ä¢ Different sensitivity and specificity


HIGH IMPACT CASE #5 (Impact Score: 70)
----------------------------------------
WHO 2022: MDS with increased blasts 2
ICC 2022: AML with in-frame bZIP mutated CEBPA

üíä Key Treatment Differences:
  ‚Ä¢ Intensive chemotherapy vs supportive care
  ‚Ä¢ Stem cell transplant eligibility differs
  ‚Ä¢ Clinical trial eligibility differs


HIGH IMPACT CASE #6 (Impact Score: 65)
----------------------------------------
WHO 2022: MDS with increased blasts 2
ICC 2022: AML with t(9;22)(q34.1;q11.2)/BCR::ABL1

üíä Key Treatment Differences:
  ‚Ä¢ Intensive chemotherapy vs supportive care
  ‚Ä¢ Stem cell transplant eligibility differs
  ‚Ä¢ Clinical trial eligibility differs

üî¨ MRD Monitoring Differences:
  ‚Ä¢ Molecular vs flow cytometry MRD monitoring
  ‚Ä¢ Different sensitivity and specificity


HIGH IMPACT CASE #7 (Impact Score: 55)
----------------------------------------
WHO 2022: AML with CEBPA mutation
ICC 2022: AML, NOS

üî¨ MRD Monitoring Differences:
  ‚Ä¢ Flow cytometry MRD only for both classifications
  ‚Ä¢ Different genetic marker identification may affect MRD strategy


HIGH IMPACT CASE #8 (Impact Score: 55)
----------------------------------------
WHO 2022: AML with CEBPA mutation
ICC 2022: AML, NOS

üî¨ MRD Monitoring Differences:
  ‚Ä¢ Flow cytometry MRD only for both classifications
  ‚Ä¢ Different genetic marker identification may affect MRD strategy


HIGH IMPACT CASE #9 (Impact Score: 75)
----------------------------------------
WHO 2022: MDS with increased blasts 2
ICC 2022: MDS/AML with mutated TP53

üíä Key Treatment Differences:
  ‚Ä¢ Intensive chemotherapy vs supportive care
  ‚Ä¢ Stem cell transplant eligibility differs
  ‚Ä¢ Clinical trial eligibility differs


HIGH IMPACT CASE #10 (Impact Score: 75)
----------------------------------------
WHO 2022: MDS with increased blasts 2
ICC 2022: MDS/AML with mutated TP53

üíä Key Treatment Differences:
  ‚Ä¢ Intensive chemotherapy vs supportive care
  ‚Ä¢ Stem cell transplant eligibility differs
  ‚Ä¢ Clinical trial eligibility differs


HIGH IMPACT CASE #11 (Impact Score: 60)
----------------------------------------
WHO 2022: MDS with increased blasts 2
ICC 2022: MDS/AML with myelodysplasia related gene mutation

üíä Key Treatment Differences:
  ‚Ä¢ Intensive chemotherapy vs supportive care
  ‚Ä¢ Stem cell transplant eligibility differs
  ‚Ä¢ Clinical trial eligibility differs


HIGH IMPACT CASE #12 (Impact Score: 60)
----------------------------------------
WHO 2022: MDS with increased blasts 2
ICC 2022: MDS/AML with myelodysplasia related cytogenetic abnormality

üíä Key Treatment Differences:
  ‚Ä¢ Intensive chemotherapy vs supportive care
  ‚Ä¢ Stem cell transplant eligibility differs
  ‚Ä¢ Clinical trial eligibility differs


HIGH IMPACT CASE #13 (Impact Score: 60)
----------------------------------------
WHO 2022: MDS with increased blasts 2
ICC 2022: MDS/AML with myelodysplasia related gene mutation

üíä Key Treatment Differences:
  ‚Ä¢ Intensive chemotherapy vs supportive care
  ‚Ä¢ Stem cell transplant eligibility differs
  ‚Ä¢ Clinical trial eligibility differs


HIGH IMPACT CASE #14 (Impact Score: 60)
----------------------------------------
WHO 2022: MDS with increased blasts 2
ICC 2022: MDS/AML with myelodysplasia related cytogenetic abnormality

üíä Key Treatment Differences:
  ‚Ä¢ Intensive chemotherapy vs supportive care
  ‚Ä¢ Stem cell transplant eligibility differs
  ‚Ä¢ Clinical trial eligibility differs


HIGH IMPACT CASE #15 (Impact Score: 60)
----------------------------------------
WHO 2022: MDS with increased blasts 2
ICC 2022: MDS/AML with myelodysplasia related gene mutation

üíä Key Treatment Differences:
  ‚Ä¢ Intensive chemotherapy vs supportive care
  ‚Ä¢ Stem cell transplant eligibility differs
  ‚Ä¢ Clinical trial eligibility differs


HIGH IMPACT CASE #16 (Impact Score: 60)
----------------------------------------
WHO 2022: MDS with increased blasts 2
ICC 2022: MDS/AML with myelodysplasia related cytogenetic abnormality

üíä Key Treatment Differences:
  ‚Ä¢ Intensive chemotherapy vs supportive care
  ‚Ä¢ Stem cell transplant eligibility differs
  ‚Ä¢ Clinical trial eligibility differs


HIGH IMPACT CASE #17 (Impact Score: 60)
----------------------------------------
WHO 2022: MDS with increased blasts 2
ICC 2022: MDS/AML, NOS, therapy related

üíä Key Treatment Differences:
  ‚Ä¢ Intensive chemotherapy vs supportive care
  ‚Ä¢ Stem cell transplant eligibility differs
  ‚Ä¢ Clinical trial eligibility differs


HIGH IMPACT CASE #18 (Impact Score: 50)
----------------------------------------
WHO 2022: MDS with biallelic TP53 inactivation
ICC 2022: MDS/AML with mutated TP53, therapy related

üíä Key Treatment Differences:
  ‚Ä¢ Intensive chemotherapy vs supportive care
  ‚Ä¢ Stem cell transplant eligibility differs
  ‚Ä¢ Clinical trial eligibility differs


HIGH IMPACT CASE #19 (Impact Score: 60)
----------------------------------------
WHO 2022: MDS, fibrotic
ICC 2022: MDS/AML with myelodysplasia related cytogenetic abnormality

üíä Key Treatment Differences:
  ‚Ä¢ Intensive chemotherapy vs supportive care
  ‚Ä¢ Stem cell transplant eligibility differs
  ‚Ä¢ Clinical trial eligibility differs


HIGH IMPACT CASE #20 (Impact Score: 70)
----------------------------------------
WHO 2022: MDS with increased blasts 2
ICC 2022: AML with in-frame bZIP mutated CEBPA

üíä Key Treatment Differences:
  ‚Ä¢ Intensive chemotherapy vs supportive care
  ‚Ä¢ Stem cell transplant eligibility differs
  ‚Ä¢ Clinical trial eligibility differs


HIGH IMPACT CASE #21 (Impact Score: 70)
----------------------------------------
WHO 2022: MDS with increased blasts 2
ICC 2022: AML with in-frame bZIP mutated CEBPA

üíä Key Treatment Differences:
  ‚Ä¢ Intensive chemotherapy vs supportive care
  ‚Ä¢ Stem cell transplant eligibility differs
  ‚Ä¢ Clinical trial eligibility differs


HIGH IMPACT CASE #22 (Impact Score: 60)
----------------------------------------
WHO 2022: MDS with increased blasts 2
ICC 2022: MDS/AML with myelodysplasia related gene mutation

üíä Key Treatment Differences:
  ‚Ä¢ Intensive chemotherapy vs supportive care
  ‚Ä¢ Stem cell transplant eligibility differs
  ‚Ä¢ Clinical trial eligibility differs


HIGH IMPACT CASE #23 (Impact Score: 60)
----------------------------------------
WHO 2022: MDS with increased blasts 2
ICC 2022: MDS/AML with myelodysplasia related gene mutation

üíä Key Treatment Differences:
  ‚Ä¢ Intensive chemotherapy vs supportive care
  ‚Ä¢ Stem cell transplant eligibility differs
  ‚Ä¢ Clinical trial eligibility differs


HIGH IMPACT CASE #24 (Impact Score: 60)
----------------------------------------
WHO 2022: MDS with increased blasts 2
ICC 2022: MDS/AML with myelodysplasia related gene mutation

üíä Key Treatment Differences:
  ‚Ä¢ Intensive chemotherapy vs supportive care
  ‚Ä¢ Stem cell transplant eligibility differs
  ‚Ä¢ Clinical trial eligibility differs


HIGH IMPACT CASE #25 (Impact Score: 60)
----------------------------------------
WHO 2022: MDS with increased blasts 2
ICC 2022: MDS/AML with myelodysplasia related gene mutation

üíä Key Treatment Differences:
  ‚Ä¢ Intensive chemotherapy vs supportive care
  ‚Ä¢ Stem cell transplant eligibility differs
  ‚Ä¢ Clinical trial eligibility differs


HIGH IMPACT CASE #26 (Impact Score: 60)
----------------------------------------
WHO 2022: MDS with increased blasts 2
ICC 2022: MDS/AML with myelodysplasia related gene mutation, therapy related

üíä Key Treatment Differences:
  ‚Ä¢ Intensive chemotherapy vs supportive care
  ‚Ä¢ Stem cell transplant eligibility differs
  ‚Ä¢ Clinical trial eligibility differs


HIGH IMPACT CASE #27 (Impact Score: 60)
----------------------------------------
WHO 2022: MDS with increased blasts 2
ICC 2022: MDS/AML with myelodysplasia related gene mutation

üíä Key Treatment Differences:
  ‚Ä¢ Intensive chemotherapy vs supportive care
  ‚Ä¢ Stem cell transplant eligibility differs
  ‚Ä¢ Clinical trial eligibility differs


HIGH IMPACT CASE #28 (Impact Score: 60)
----------------------------------------
WHO 2022: MDS with increased blasts 2
ICC 2022: MDS/AML with myelodysplasia related gene mutation

üíä Key Treatment Differences:
  ‚Ä¢ Intensive chemotherapy vs supportive care
  ‚Ä¢ Stem cell transplant eligibility differs
  ‚Ä¢ Clinical trial eligibility differs


HIGH IMPACT CASE #29 (Impact Score: 60)
----------------------------------------
WHO 2022: MDS with increased blasts 2
ICC 2022: MDS/AML with myelodysplasia related gene mutation

üíä Key Treatment Differences:
  ‚Ä¢ Intensive chemotherapy vs supportive care
  ‚Ä¢ Stem cell transplant eligibility differs
  ‚Ä¢ Clinical trial eligibility differs


HIGH IMPACT CASE #30 (Impact Score: 60)
----------------------------------------
WHO 2022: MDS with increased blasts 2
ICC 2022: MDS/AML with myelodysplasia related gene mutation

üíä Key Treatment Differences:
  ‚Ä¢ Intensive chemotherapy vs supportive care
  ‚Ä¢ Stem cell transplant eligibility differs
  ‚Ä¢ Clinical trial eligibility differs


HIGH IMPACT CASE #31 (Impact Score: 60)
----------------------------------------
WHO 2022: MDS with increased blasts 2
ICC 2022: MDS/AML with myelodysplasia related gene mutation

üíä Key Treatment Differences:
  ‚Ä¢ Intensive chemotherapy vs supportive care
  ‚Ä¢ Stem cell transplant eligibility differs
  ‚Ä¢ Clinical trial eligibility differs


HIGH IMPACT CASE #32 (Impact Score: 65)
----------------------------------------
WHO 2022: MDS with increased blasts 2
ICC 2022: AML with t(9;22)(q34.1;q11.2)/BCR::ABL1

üíä Key Treatment Differences:
  ‚Ä¢ Intensive chemotherapy vs supportive care
  ‚Ä¢ Stem cell transplant eligibility differs
  ‚Ä¢ Clinical trial eligibility differs

üî¨ MRD Monitoring Differences:
  ‚Ä¢ Molecular vs flow cytometry MRD monitoring
  ‚Ä¢ Different sensitivity and specificity


HIGH IMPACT CASE #33 (Impact Score: 60)
----------------------------------------
WHO 2022: MDS with increased blasts 2
ICC 2022: MDS/AML with myelodysplasia related gene mutation

üíä Key Treatment Differences:
  ‚Ä¢ Intensive chemotherapy vs supportive care
  ‚Ä¢ Stem cell transplant eligibility differs
  ‚Ä¢ Clinical trial eligibility differs


üìã MEDIUM CLINICAL IMPACT CASES (Score 25-49)
============================================================
Found 33 cases with moderate clinical implications

‚Ä¢ Moderate Clinical Impact: 33 cases
  Example: WHO 'MDS with increased blasts 2' vs ICC 'MDS/AML, NOS'
  Key difference: Intensive chemotherapy vs supportive care

üî• CRITICAL: DISEASE TYPE DISAGREEMENTS
============================================================
Cases where classifications fall into different disease categories
(These have the highest clinical impact)

WHO‚ÜíAML, ICC‚ÜíMDS: 1 cases
WHO‚ÜíMDS, ICC‚ÜíAML: 56 cases
Other disagreements: 15 cases

Most Common Pattern - WHO‚ÜíMDS, ICC‚ÜíAML:
  WHO: MDS with increased blasts 2
  ICC: MDS/AML, NOS
  Clinical Impact: Supportive care vs intensive chemotherapy

üìä CLINICAL IMPACT STATISTICS
============================================================
Average Clinical Impact Score: 21.6
Maximum Clinical Impact Score: 95
Cases affecting treatment decisions: 69 (33.8%)
Cases affecting MRD monitoring: 24 (11.8%)
Cases affecting prognosis: 81 (39.7%)

REPORT METADATA
----------------------------------------
Generated: 2025-06-06 23:13:06
Analysis: WHO 2022 vs ICC 2022 classifications
Focus: Clinical impact assessment
================================================================================